Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Lafyatis, Robert | Person |
Why?
|
| Simms, Robert | Person |
Why?
|
| Trojanowska, Maria | Person |
Why?
|
| Bujor, Andreea | Person |
Why?
|
| Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease. | Academic Article |
Why?
|
| Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity. | Academic Article |
Why?
|
| Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. | Academic Article |
Why?
|
| York, Michael | Person |
Why?
|
| Cyclophosphamide improves vascular abnormalities in endothelial cell-specific Fli1 knockout mice mimicking scleroderma-related vasculopathy | Academic Article |
Why?
|
| Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. | Academic Article |
Why?
|
| Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis. | Academic Article |
Why?
|
| Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. | Academic Article |
Why?
|
| Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. | Academic Article |
Why?
|
| Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. | Academic Article |
Why?
|
| Scleroderma--developing measures of response. | Academic Article |
Why?
|